Urogenital Infections and Inflammations

T.E. Bjerklund Johansen, F. M.E. Wagenlehner, Y.-H. Cho, T. Matsumoto, J. N. Krieger, D. Shoskes, K. Naber

Comprehensive neuromuscular assessment of chronic pelvic pain (including BPS/IC)

 Jörgen Quaghebeur 1


1 Department of Urology, University Hospital Antwerp and University Antwerp, Antwerp, Belgium

Abstract

Patients diagnosed with chronic pelvic pain syndrome (CPPS) consult with a variety of symptoms related to organs in the pelvic region, in the absence of a proven infection, pathology or confusable disease. The ESSIC classification of bladder pain syndrome (BPS) according to the results of cystoscopy and of biopsy has to be used for the differentiation between BPS subtypes. A systematic approach is needed trying to understand the problem in CPPS. A four step plan with attention for emotional factors is indicated to assess these patients. A thorough clinical investigation includes a physical assessment as well. Assessing CPPS patients shows musculoskeletal pain that is not restricted to the pelvis. The whole spine can be painful. Manual applied neurodynamic tests and local palpation show mechanosensitivity of the pudendal nerve in most of cases, although almost all other nerves of the lumbosacral plexus can have minor nerve injuries. One patient can have multiple mononeuropathies simultaneously. A thorough physical assessment can indicate the anatomical origins of pain and help to determine the therapeutic approach. The variety of symptoms suggesting simultaneous organ dysfunction in multiple systems, indicate the need for a multidisciplinary approach.


Abbreviations

AIGS: Abnormal impulse generated site
CPP: Chronic pelvic pain
CPPS: Chronic pelvic pain syndrome
CRPS: Complex regional pain syndrome
ESSIC: International Society for the Study of BPS
IBS: Irritable bowel syndrome
ICSI: Interstitial cystitis symptom index
LUT: Lower urinary tract
NIH-CPSI: National Institutes of Health – chronic prostatitis index
PD-Q: PainDETECT questionnaire
PUF: Pain and urgency, frequency questionnaire
QoL: Quality of life
S-LANSS: Self-completed Leeds Assessment of Neuropathic Symptoms and Signs

Introduction

Chronic pelvic pain syndrome (CPPS) is characterized by persistent genitourinary pain, associated with symptoms perceived to be related to organs in the pelvic region, in the absence of a proven infection or other identifiable pathology (e.g. lower urinary tract (LUT), sexual, bowel, pelvic floor or gynaecological) [1], [2], [3], [4], [5], [6]. CPPS has an important negative impact on the quality of life [6]. The complexity and interactive aspects of the CPPS and its multidisciplinary management underlines the need for a detailed diagnosis. To discriminate the different syndromes within CPPS remains a challenge because the overlap of symptoms of different systems. The pain is mostly perceived in different structures related to the pelvis and poorly localized. From the history, investigations and physical assessment the syndrome can be determined. Painful areas and pain points have to be convincingly reproduced by local palpation [7]. The CPPS are described in Table 1.

Table 1: Overview of the chronic pelvic pain syndromes [3]

Chronic pelvic pain syndromes (CPPS)
Urological pain syndromes

 

Bladder pain syndrome (BPS)* pain in the urinary bladder region, accompanied by at least one other symptom:
  • pain worsening with bladder filling
  • day-time and/or night-time urinary frequency
Urethral pain syndrome pain perceived in the urethra
Penile pain syndrome pain within the penis that is not primarily in the urethra
Prostate pain syndrome pain which is convincingly reproduced by prostate palpation
Scrotal pain syndrome pain localized within the organs of the scrotum; generic term when the site of the pain is not clearly testicular or epididymal
Testicular pain syndrome pain perceived in the testes
Post-vasectomy pain syndrome scrotal pain syndrome that follows vasectomy
Epididymal pain syndrome pain perceived in the epididymis
Gynaecological pain syndromes
Vulvar pain syndrome vulvar pain (according ISSVD: vulvodynia is vulvar pain that is not accounted for by any physical findings)
Generalized vulvar pain syndrome pain/burning cannot be consistently and precisely localised by point-pressure mapping
Localized vulvar pain syndrome pain that can be consistently and precisely localised by point-pressure mapping to one or more portions of the vulva
Vestibular pain syndrome pain that can be localised by point-pressure mapping to the vestibule or is well perceived in the area of the vestibule
Clitoral pain syndrome pain that can be localised by point-pressure mapping to the clitoris or is well perceived in the area of the clitoris
Endometriosis-associated pain syndrome pain with laparoscopicly confirmed endometriosis, when the symptoms persist despite adequate endometriosis treatment
CPPS with cyclical exacerbations non-gynaecological organ pain that frequently shows cyclical exacerbations (e.g., IBS or BPS) and differs from dysmenorrhoea, in which pain is only present with menstruation
Dysmenorrhoea pain with menstruation
Musculoskeletal system
Pelvic floor muscle pain syndrome pelvic floor pain that may be associated with overactivity of or trigger points within the pelvic floor muscles or trigger points found in muscles, such as the abdominal, thigh and paraspinal muscles and even those not directly related to the pelvis
Coccyx pain syndrome pain perceived in the region of the coccyx
Gastrointestinal pelvic pain syndromes
Irritable bowel syndrome (IBS) pain perceived in the bowel, according to the Rome III criteria
Chronic anal pain syndrome pain perceived in the anus
Intermittent chronic anal pain syndrome pain unrelated to the need to or the process of defecation, that seems to arise in the rectum or anal canal
Pudendal pain syndrome  
* ESSIC proposal
(adapted from [2])

One specific form of CPPS is interstitial cystitis/ bladder pain syndrome (IC/BPS) [8]. It presents with perceived bladder pain ranging from mild discomfort to severe disability, and a variety of urinary symptoms. ESSIC defined BPS as pain in the urinary bladder region, accompanied by at least one other symptom (pain worsening with bladder filling; day-time and/or night-time urinary frequency). In IC/BPS the lower urinary tract symptoms may be accompanied with symptoms in other systems (e.g. bowel, sexual, pelvic floor, gynaecological or musculoskeletal). To classify the types of bladder pain syndrome, ESSIC determined a classification system according to the results of cystoscopy with hydrodistension and of biopsy [9]. The differentiation between bladder pain syndrome (BPS) subtypes (e.g. type 3C BPS and non-type 3C BPS) using questionnaires remains unclear [10]. Table 2 shows the ESSIC classification system for bladder pain syndrome.

Table 2: ESSIC classification of BPS according to the results of cystoscopy and of biopsy [9]

  ESSIC classification of types of BPS
   Cystoscopy with hydrodistention
Biopsy Not done Normal Glomerulationsa Hunner’s lesionb
Not done XX 1X 2X 3X
Normal XA 1A 2A 3A
Inconclusive XB 1B 2B 3B
Positivec XC 1C 2C 3C

a Cystoscopy: glomerulations grade 2–3.
b With or without glomerulations.
c Histology showing inflammatory infiltrates and/or detrusor mastocytosis and/or granulation tissue and/or intrafascicular fibrosis.

CPPS must be distinguished from forms of chronic pelvic pain that have well-defined causes such as infection, endometriosis, haemorrhoids, anal fissure, pudendal neuropathy, sacral spinal cord pathology, vascular and cutaneous disease, psychiatric conditions) [2], [11].

Diagnosis and managing CPP

Specific disease associated pelvic pain needs an appropriate treatment according to the designated disease guideline. In CPPS, the variety of symptoms suggesting simultaneous organ dysfunction in multiple systems, indicate the need for a multidisciplinary approach. Figure 1 shows the algorithm for diagnosis and management of CPP.

Figure 1: Algorithm for diagnosis and management of CPP [3]
(adapted from [2])

To determine which of the different syndromes is present remains a challenge because of the overlapping symptoms and the interrelations of structures in the pelvic region. History, examination and investigations may suggest the pain as being generated from a specified anatomical pelvic area (e.g. BPS, PPS, pudendal nerve pain syndrome). On the other hand, visceral pain, can refer to a cutaneous site, and be accompanied by muscular hyper tonicity [12], [13], emotional and autonomic responses [14], [15]. The common innervation of the pelvic organs and cross sensitization can partially explain the functional interference between systems [16], [17]. Complicating matters further, pain mechanisms such as central sensitization and chronic regional pain syndrome are important chronic pain states frequently identified in the BPS patient [18].

Given the complexity of pain generation in the patient presenting with chronic pelvic pain, a systematic approach for evaluation is strongly recommended through a ‘four-step protocol’ [6], [19], [20]. A systematic approach to determine pain mechanisms (e.g. referred pain, local inflammation, central/peripheral sensitisation), and the anatomical painful areas aims at obtaining supplementary information to refine the therapeutic management before jumping into various treatment attempts [3].

A thorough clinical assessment: the four-step plan

The complexity and interactive aspects of the CPPS implies the eventual need for multidisciplinary management. Once the diagnosis CPPS has been confirmed, a further clinical assessment can help to chose the best therapeutic approaches. A thorough clinical assessment is described here, based on the four-step protocol for investigation of CPPS. The thorough clinical assessment aims at acquiring a maximum of diagnostic information. A thorough clinical assessment takes about 30 minutes, and can easily be done by a well trained physical therapist or osteopath. Table 3 shows the four steps to undertake for obtaining essential information.

Table 3: The thorough clinical assessment: four-step plan

  4-step plan
Step I History with questioning for complaints in other systems
Step II Evaluation of previous assessments and reports
Step III

Thorough clinical assessment

  • neurologic
  • hernias
  • external gender organs
  • small pelvis (rectal/vaginal)
Step IV

Extensive clinical assessment of the musculoskeletal system

  • full spine
  • pelvic girdle
  • muscles
  • tendons
  • pain points

Step I: history with questioning for complaints in other systems

History taking will often develop a list of symptoms which are related to different pelvic structures. In IC/BPS a voiding log for frequency, urgency, and nocturia is needed. Bowel habits must be investigated. Sexual complaints and impact of the symptoms on QoL must be evaluated. One should ask for description of the pain (e.g. area, onset, presentation, burning feeling related to urination), and interfering factors of complaints. The pain description has to be scrutinized in detail (e.g. episodic versus constant, single versus several locations, time relation to voiding, defecation, sexual activities, and bother). Attention for psychological, behavioural, and social problems is needed taking a history [21], [22], [23]. The social history and economic burden as a result of the illness should not be underestimated.

Table 4: Overview of symptoms in different systems in CPPS

 Symptoms in CPPS

Urological system

  • pain worsening with bladder filling
  • pain relieved by voiding
  • micturitional pain
  • frequency
  • urgency
  • nocturia
  • penile pain
  • prostate pain
  • scrotal pain
  • pelvic floor pain
  • urinary incontinence

Gynaecological system

  • vulvar pain (according to ISSVD: vulvodynia)
  • pelvic pain with cyclic exacerbations
  • period related pain
  • dyspareunia

Musculoskeletal system

  • musculoskeletal pain of pelvic area (e.g.: pelvic floor muscle pain)
  • pain increasing while sitting

Gastrointestinal system

  • bowel symptoms (e.g. constipation, diarrhea)
  • pain in anal area or perceived in rectal canal

Pudendal pain

  • perineal pain perceive in perineal area (e.g.: burning)

Questionnaires can be useful for evaluation of symptoms (e.g. McGill [24], Pollard [25], [26], [27], NIH-CPSI [28], [29], [30], [31], ICSI [32], PUF [33], [34], [35] questionnaires). Because of their specific properties, they do not give the same kind of information and the results must be interpreted separately for each patient [36]. The PainDETECT questionnaire (PD-Q) and the self-completed Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) can help to give additional information about neuropathic pain in BPS [37], [38], [39], [40]. It has been shown that neuropathic pain screening questionnaires have limited measurement properties. They do not replace a thorough clinical assessment [41]. The University of Wisconsin IC scale and the Genitourinary Pain Index (GUPI) can be used to indicate the severity of symptoms in BPS [42], [43], [44], [45].

Questionnaires for evaluation of mental distress, coping with pain and catastrophizing symptoms (e.g. Positive and Negative Affect Schedule (PANAS), Chronic Pain Coping Inventory (CPCI), Pain Catastrophizing Scale (PCS)) can be used for the evaluation of the emotional impact on pain and symptoms, as a result of BPS [37], [46], [47], [48], [49].

Step II: evaluation of previous assessments and reports

Information from previous technical and specialist assessments need to be taken in account, including all radiographic examinations as RX, NMR, CT and lab data [50]. These previous reports can indicate the presence of confusable diseases [9]. This time-consuming initial effort is a needed investment to avoid fragmented, multiple visits with poor results during many years.

Step III: thorough clinical assessment

This includes a clinical neurologic assessment, palpation of the external sexual organs, and a palpation by rectal/vaginal ways.

Clinical neurologic assessment

The clinical neurologic assessment includes an examination of the lumbosacral plexus evaluating motor, sensory function, and reflexes [51].

With an EMG, the clinical signs can be confirmed. In absence of EMG findings, pain of neuropathic origin is not excluded. Neuropathic pain can present without evidence for nerve injury (e.g. EMG) [52], [53], [54]. An EMG is needed when a nerve injury is expected and before neurodynamic testing and treatment, when clinical signs exist. A minor neuropathy or minor nerve injury is a peripheral mononeuropathy in which EMG does not indicate a malfunction, but in which the normal physiology of the nerve is disturbed.

Peripheral nerve entrapments and minor nerve injuries

Entrapment neuropathies share a common pathophysiology: localized ischemia, endoneurial edema, and vascular impairment from ongoing mechanical pressure or longitudinal stress on a nerve [54], [55]. Peripheral nerve entrapment (e.g. mononeuropathy), compression, or irritation of nerve roots forming the lumbosacral plexus may cause neuropathic pain and sustain sensitization [56]. In early nerve compression the symptoms are caused by vascular impairment, and initial changes occur at the blood-nerve barrier. There is no lymphatic drainage of the endoneurial space [55] making it susceptible for inflammation. Mononeuropathy can be an indication of a disturbed homeostatic endoneurial microenvironment which gives an indication for mechanosensitivity treatment.

The viscoelastic properties of nerve tissue may accommodate for a modest increase in length. Normal physical stresses upon a nerve during limb movement may be sufficient to provoke mechanosensitivity, suggesting peripheral sensitization. Peripheral nerve sensitization can be present even in absence of altered EMG [53], [54]. The neurologic assessment can be completed with manual neurodynamic testing indicating movement restrictions and mechanosensitivity of the peripheral nerves of the lumbosacral plexus [3]. Neurodynamic tests showing mechanosensitivity of peripheral nerves, indicate the need for specific mobilisation of the nervous system [57], [58], [59].

Neurodynamic testing

Neurodynamic tests are manual applied techniques to assess the mobility of peripheral nerves. Nervous structures such as nerves and the spinal cord must be able to move freely during movement of the limbs and spine. Decreased ability to move will result in circulatory disturbances inside a nervous structure and pain mediators will install. Neurodynamic tests and neurodynamic treatment are contra indicated when a nerve injury (e.g. neuropraxia, axonotmesis, and neurotmesis) or polyneuropathy is confirmed. Neurodynamic tests can show mechanosensitivity indicating a mononeuropathy suggesting entrapment of a nerve [3].

Neurodynamic techniques

Applying a moderate stress by increasing the length of the nerve by limb movement (tensioning), or gentle local palpation of a nerve itself, can show the existence of mechanosensitivity indicating a minor neuropathy [60], [61]. Mechanosensitivity in peripheral nerves may occur in almost all peripheral nerves of the lumbosacral plexus and can be assessed and treated with a neurodynamic approach restoring the circulation within the nerve with gliding and tensioning techniques [57], [58], [59]. Gliding means the ability of a nerve to move aside to the surrounding nerve bed during limb movement, and is also termed ‘displacement’ [54]. This approach was also described for upper limb peripheral mechanosensitivity testing [62]. Neurodynamic testing also includes manually applied moderate stress testing by increasing the length of the nerve by limb movement (tensioning). Neurodynamic tension testing or local palpation can show the existence of minor neuropathies [57], [58]. Local applied gentle palpation of the nerve itself can show peripheral mechanosensitivity as well. Neurodynamic assessment can show minor neuropathies and is important when treating chronic pain [60], [61]. The neurodynamic tests of the lumbosacral plexus can indicate mechanosensitivity and be considered as an abnormal impulse generated site (AIGS) or ectopic activity, maintaining sensitization [63]. Central sensitization can be maintained by permanent peripheral sensory neuroinflammation [64]. Applying a brush and pointed stimuli to the painful area can show allodynia or hyperalgesia.

Mechanosensitivity in the lumbosacral plexus, can be confirmed by local palpation or by using neurogenic tension tests at the level of the sciatic, iliohypogastric, ilioinguinal, genitofemoral, obturator, lateral cutaneous femoral, perineal, dorsal, and the medial, lateral and inferior cluneal nerves. Increase of pain during “straight leg raise” can possibly point out neuropathic pain of the sciatic nerve. If lying on the back provokes pain due to hip extension combined with internal rotation at the level of the groin or genital organs this can suggest a minor neuropathic problem at the level of the ilioinguinal n. (L1) or genitofemoral n. (L1–L2). Ilioinguinal and genitofemoral nerve mechanosensitivity can be shown by palpating the internal and external inguinal annular ring. When an increase of pain occurs during hip extension with adduction, a minor neuropathy of the lateral cutaneous femoral n. (L2–L3) can be pointed out. Increase of pain in the adductor region, with hip abduction can indicate a minor neuropathy at the level of the obturator n. (L2–L3–L4).

The pudendal pain syndrome should be considered as increased mechanosensitivity of the pudendal nerve. Instead, pudendal neuropathy has been defined as a specific disease or pathology (nerve injury) with pain as a result and is not an indication for neurodynamic treatment [65]. Extensive neurodynamic testing aspects and palpation procedures of the lumbosacral plexus peripheral nerves are described in Table 5.

Table 5: Overview of neurodynamic tests of the lumbosacral plexus

 nerve(s) root pain area neurodynamic test palpation
area approach
iliohypogastric L1 hypogastric- & lat. gluteal hip ext. & endorot. hypogastric EA, BM, VA
ilioinguinal L1 inguinal hip ext. & endorot. inguinal ring, spermatic cord, scrotal EA, BM, VA
genitofemoral L1–L2 sup. 1/3th ant. femoral, inguinal, scrotal, vulvar hip ext. & endorot. inguinal ring, spermatic cord, scrotal EA, BM, VA
lat. fem. cut. L2–L3 lat. aspect of the thigh hip ext. & add. med. ASIS EA
obturator L2–L4 lower med. aspect of the thigh, above the knee hip abd. obturator foramen RA
femoral L2–L4 ant.- med. aspect of the thigh hip ext. inguinal, lat. femoral artery (hip ext.) EA
saphenous L2–L4 ant.- med. aspect of the leg & infrapatellar hip ext. & plantar flex., ev. ankle med.-inf. patella, ant. of med. malleolus EA
sciatic L4–S3 gluteal, post. aspect leg & lat. foot hip flex., add., endorot. & ev./inv. ankle 1/2 between major trochanter & coccyx EA
post. fem. cut. S1–S3 post. aspect of the thigh hip flex., add., endorot. med. post. aspect of the thigh EA
tibial L4–S3 med. malleolus, plantar, calcaneal hip flex. add., endorot. & dorsal flex./ev. ankle 1/2 popliteal fossa EA
sural (tibial) S1–S2 post.- lat. aspect of the calf, lat. aspect of foot hip flex. add., endorot. & dorsal flex./ev. ankle post. lat. malleolus EA
peroneal (com) L4–S2 1/4th sup. ant.-post. aspect of lower extremity hip flex. add., endorot. & dorsal flex./ev. ankle post. aspect of sup. head of fibula EA
peroneal (super) L4–S2 post.- lat. aspect lower extremity & dorsum foot hip flex. add., endorot. & dorsal flex./ev. ankle foot dorsum EA
peroneal (deep) L4–S2 lower extremity & triangle between 1st & 2nd toe local palpation is indicated triangle between 1st & 2nd toe EA
pudendal* S2–S4 perineal floor local palpation is indicated pudendal canal RA
perineal* S2–S4 perineal floor local palpation is indicated perineal floor EA
dorsal* S2–S4 dorsal aspect penis, clitoris local palpation is indicated dorsal aspect penis EA
lat. cluneal L1–L3 post. aspect of iliac crest heterolat. side bending spine, hip flex./endo post.-lat. aspect of iliac crest EA
med. cluneal S1–S3 post. - inf. sacral area heterolat. side bending spine, hip flex./endo post.-med. aspect of sacrum EA
inf. cluneal S1–S3 sciatic tuberosity local palpation is indicated inf.-lat. sciatic tuberosity EA
* must be evaluated by palpation; ev.: eversion; inv.: inversion; ASIS: anterior superior iliac spine; BM: bimanual palpation; EA: external assessment; VA: vaginal assessment; RA: rectal assessment

A study [66] showed at least one neuropathy in 88% of CPPS patients (n=26), while 42% had multiple neuropathies [67]. One patient had mechanosensitivity in 12 nerves or nerve branches. In 12% no mechanosensitivity, could be shown. Compared to other nerves of the lumbosacral plexus with mechanosensitivity, mainly the pudendal nerve (85%) was painful during palpation of Alcock’s channel. Femoral, sciatic, sural, peroneal, and tibial neuropathies were shown as well in 4%.

Electrodiagnostic evaluation of the sensory function

Electrodiagnostic evaluation of the sensory function determining current perception thresholds can be an aid, evaluating neuropathy and afferent nerve activity from the LUT [19], [68]. This evaluation method has been suggested for pain assessment in research and clinic. Studies trying to assess sensory function in a semi objective way resulted in a wide variability of current perception thresholds (CPTs) in healthy volunteers and a weak agreement between normative data of control groups [69], [70].

Neurodynamic tests to investigate increased mechanosensitivity demonstrated a moderate reliability [62]. Therefore we can conclude that neurodynamic testing in CPPS is important.

Clinical assessment for hernias

Abdominal, inguinal or femoral hernias sometimes manifest themselves with CPP, groin pain or pain at the gender organs. We can distinguish inguinal and femoral hernias by palpation and where pain is provoked. Also a hernia at the level of the external or internal inguinal ring can often be found by palpation. With palpatory provoked pain of the abdominal wall, hernias at the level of the Spighelian line and umbilical hernias must be excluded [71]. A hernia in some cases can be diagnosed by palpation and /or by using the valsalva-manoeuvre standing and also in standing position with light flexion of the trunk. Ultrasound evaluation can confirm. Some hernias only manifest themselves with the Valsalva manoeuvre with the trunk in an anterior position and are missed during ultrasound, because this examination is usually conducted with the patient lying on the back. The Carnet’s sign (increased pain with tensing abdomen) can indicate abdominal wall pain [72].

Palpation of external genitalia

Observe the extern gender organs for rash, secretion, abscess formation, perineal fistula, atrophic disorders or signs of trauma. In male patients also palpate the testis, epididymis, the spermatic cord and the penis. Is there a scrotal mass? In women the palpation of the labia, vestibular glands and the urethra must be included and localized genital pain points must be differentiated from generalized vulvar pain. Q-Tip testing can show the pain area.

Palpation of the pelvic floor (rectal/vaginal assessment)

The pelvic floor function must be evaluated distinguishing the function of the urogenital diaphragm, the levator muscle and the anal sphincter. A score of power, endurance and exhaustion is noted (Oxford scale) [73], [74]. When on demand relaxation is a problem, voiding or defecation problems are suspected, indicating the need for uroflow and further bowel assessment. A study showed palpatory provoked pain in at least one part of the pelvic floor in men and women with CPPS. The pelvic floor scores were not weak in general [67].

With palpation the pain can be differentiated at the level of the pudendal canal or the area of the obturator foramen. The sacrotuberous and sacrospinous ligaments can be sensitive, indicating ligamentary stress or neuropathic pain of perforating cutaneous branches. Coccygeal pain must be determined and may be accompanied by pelvic floor hypertonia. Pain can be differentiated by using palpation at the different parts of the pelvic floor and indicated pain points. Sacrococcygeal joint instability must be excluded and can be confirmed with X-ray of the patient in a standing and sitting position [75].

Myofascial trigger points have been defined as hyperirritable spots in a skeletal muscle that are associated with a hypersensitive palpable nodule in a taut band [76]. The spot is tender when pressed and can give rise to characteristic referred pain [77]. Figure 2 shows the myofascial pain points as described by Anderson et al. [78].

Figure 2: Myofascial trigger points of the pelvis
(adapted from the “Stanford Protocol” [79])

Step IV: extensive clinical assessment of the musculoskeletal system

The clinical assessment of the musculoskeletal system in patients with CPP can be excelled in different postures and is not restricted to the pelvis. Next to the posture, movement limitations need to be confirmed at the level of the complete spine and pelvis. Observe the posture in standing, lying and sitting position. Let the patient indicate the area of the pain [80], [81]. Spinal mobility is assessed with palpation, and active and passive movements. Asymmetry in the amplitude is noted, with attention to a unilateral shorter lower limb or scoliosis. The joint play of the sacroiliac joints, the pubis and the sacrococcygeal joints must be assessed. The greater trochanter and the ischial tuberosity must be palpated to indicate ischial or trochanteric bursitis. In the buttock area a minor neuropathy of the inferior cluneal nerve, tendonitis must be differentiated. Osteogenic pain can indicate periostitis.

CPPS is often accompanied with articular restrictions or muscular pain (e.g. low back pain, pelvic girdle pain), indicating the attention for an extensive assessment of the musculoskeletal system [82]. We determined pain musculoskeletal origin in 88% of CPPS patients (n=23) [67]. The main areas of musculoskeletal pain were the lumbar and sacrococcygeal area [66]. Referred pain, hypertonic muscular activity and articular movement restrictions may maintain the viscous circle of symptoms related to CPPS. Differentiating all the symptoms in multiple systems, including the clinical signs of the musculoskeletal system can indicate a more appropriate approach in a holistic context, dealing with CPPS.

The evaluation as described in step 3 and 4 is highly recommendable although all suggested measures are not manageable by the urologist. A multidisciplinary team is needed to deal with the problem, including gynaecologists, neurologists, neurophysiologists, proctologists, sexologists, psychologists. Osteopathic physicians and physical therapists can be an aid assessing the patient in a holistic way, with attention to the interference between visceral and musculoskeletal symptoms (e.g. pelvic girdle pain, low back complaints, pain points, and fascial movement restrictions). Specialized centres are needed, with the thorough clinical investigation as an integral part of the assessment before the multidisciplinary team is consulted.


References

[1] Fall M, Baranowski AP, Elneil S, Engeler D, Hughes J, Messelink EJ, Oberpenning F, de C Williams AC; European Association of Urology. EAU guidelines on chronic pelvic pain. Eur Urol. 2010 Jan;57(1):35-48. DOI: 10.1016/j.eururo.2009.08.020
[2] Engeler D, Baranowski AP, Elneil S, Hughes J, Messelink EJ, Oliveira P, van Ophoven A, de C. Williams AC. Guidelines on Chronic Pelvic Pain. European Association of Urology; 2012 (cited 13 July 2017). Available from: https://uroweb.org/wp-content/uploads/24_Chronic_Pelvic_Pain_LR-March-23th.pdf
[3] Quaghebeur J, Wyndaele JJ. Chronic pelvic pain syndrome: role of a thorough clinical assessment. Scand J Urol. 2015 Apr;49(2):81-9. DOI: 10.3109/21681805.2014.961546
[4] Fall M, Baranowski AP, Elneil S, Engeler D, Hughes J, Messelink EJ, Oberpenning F, de C Williams AC. EAU Guidelines on chronic pelvic pain. European Association of Urology; 2008. Available from: https://uroweb.org/wp-content/uploads/22_Chronic_Pelvic_Pain-2008.pdf
[5] Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Am J Obstet Gynecol. 2002 Jul;187(1):116-26.
[6] Quaghebeur J, Wyndaele JJ. Prevalence of lower urinary tract symptoms and level of quality of life in men and women with chronic pelvic pain. Scand J Urol. 2015 Jun;49(3):242-9. DOI: 10.3109/21681805.2014.984325
[7] Engeler D, Baranowski AP, Borovicka J, Cottrell A, Dinis-Oliveira P, Elnei S, Hughes J, Messelink EJ, van Ophoven A, Reisman Y, de C. Williams AC. Guidelines on Chronic Pelvic Pain: European Association of Urology. 2014 (cited 13 July 2017). Available from: https://uroweb.org/wp-content/uploads/26-Chronic-Pelvic-Pain_LR.pdf
[8] Ke QS, Kuo HC. Pathophysiology of interstitial cystitis/bladder pain syndrome. Tzu Chi Medical Journal. 2015. 27(4):139-44. DOI: 10.1016/j.tcmj.2015.09.006
[9] van de Merwe JP, Nordling J, Bouchelouche P, Bouchelouche K, Cervigni M, Daha LK, Elneil S, Fall M, Hohlbrugger G, Irwin P, Mortensen S, van Ophoven A, Osborne JL, Peeker R, Richter B, Riedl C, Sairanen J, Tinzl M, Wyndaele JJ. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol. 2008 Jan;53(1):60-7. DOI: 10.1016/j.eururo.2007.09.019
[10] Quaghebeur J, Wyndaele JJ. Bladder pain syndrome (BPS): Symptom differences between type 3C BPS and non-type 3C BPS. Scand J Urol. 2015;49(4):319-20. DOI: 10.3109/21681805.2014.982170
[11] Fall M, Baranowski AP, Fowler CJ, Lepinard V, Malone-Lee JG, Messelink EJ, Oberpenning F, Osborne JL, Schumacher S; European Association of Urology. EAU guidelines on chronic pelvic pain. Eur Urol. 2004 Dec;46(6):681-9. DOI: 10.1016/j.eururo.2004.07.030
[12] Giamberardino MA. Referred muscle pain/hyperalgesia and central sensitisation. J Rehabil Med. 2003 May;(41 Suppl):85-8. DOI: 10.1080/16501960310010205
[13] Giamberardino MA, Affaitati G, Lerza R, Vecchiet L. Referred muscle pain and hyperalgesia from viscera: clinical and pathophysiological aspects. Basic Appl Myol. 2004.14(1):23-8.
[14] Gebhart GF, Ness TJ. Central mechanisms of visceral pain. Can J Physiol Pharmacol. 1991 May;69(5):627-34. DOI: 10.1139/y91-093
[15] Yilmaz U, Liu YW, Berger RE, Yang CC. Autonomic nervous system changes in men with chronic pelvic pain syndrome. J Urol. 2007 Jun;177(6):2170-4; discussion 2174. DOI: 10.1016/j.juro.2007.01.144
[16] Pezzone MA, Liang R, Fraser MO. A model of neural cross-talk and irritation in the pelvis: implications for the overlap of chronic pelvic pain disorders. Gastroenterology. 2005 Jun;128(7):1953-64. DOI: 10.1053/j.gastro.2005.03.008
[17] Ustinova EE, Fraser MO, Pezzone MA. Cross-talk and sensitization of bladder afferent nerves. Neurourol Urodyn. 2010;29(1):77-81. DOI: 10.1002/nau.20817
[18] Kaya S, Hermans L, Willems T, Roussel N, Meeus M. Central sensitization in urogynecological chronic pelvic pain: a systematic literature review. Pain Physician. 2013 Jul-Aug;16(4):291-308.
[19] Wyndaele JJ. Investigating afferent nerve activity from the lower urinary tract: highlighting some basic research techniques and clinical evaluation methods. Neurourol Urodyn. 2010;29(1):56-62. DOI: 10.1002/nau.20776
[20] Quaghebeur J, Wyndaele JJ. A review of techniques used for evaluating lower urinary tract symptoms and the level of quality of life in patients with chronic pelvic pain syndrome. Itch & Pain. 2015;2: e659. DOI: 10.14800/ip.659
[21] McNaughton Collins M. The impact of chronic prostatitis/chronic pelvic pain syndrome on patients. World J Urol. 2003 Jun;21(2):86-9. DOI: 10.1007/s00345-003-0331-6
[22] Tripp DA, Nickel JC, Wang Y, Litwin MS, McNaughton-Collins M, Landis JR, Alexander RB, Schaeffer AJ, O'Leary MP, Pontari MA, Fowler JE Jr, Nyberg LM, Kusek JW; National Institutes of Health-Chronic Prostatitis Collaborative Research Network (NIH-CPCRN) Study Group. Catastrophizing and pain-contingent rest predict patient adjustment in men with chronic prostatitis/chronic pelvic pain syndrome. J Pain. 2006 Oct;7(10):697-708. DOI: 10.1016/j.jpain.2006.03.006
[23] Ku JH, Kim SW, Paick JS. Quality of life and psychological factors in chronic prostatitis/chronic pelvic pain syndrome. Urology. 2005 Oct;66(4):693-701. DOI: 10.1016/j.urology.2005.04.050
[24] Melzack R. The McGill pain questionnaire: from description to measurement. Anesthesiology. 2005 Jul;103(1):199-202. DOI: 10.1097/00000542-200507000-00028
[25] Pollard CA. Preliminary validity study of the pain disability index. Percept Mot Skills. 1984 Dec;59(3):974. DOI: 10.2466/pms.1984.59.3.974
[26] Tait RC, Chibnall JT, Margolis RB. Pain extent: relations with psychological state, pain severity, pain history, and disability. Pain. 1990 Jun;41(3):295-301.
[27] Tait RC, Pollard CA, Margolis RB, Duckro PN, Krause SJ. The Pain Disability Index: psychometric and validity data. Arch Phys Med Rehabil. 1987 Jul;68(7):438-41.
[28] McNaughton Collins M, Pontari MA, O'Leary MP, Calhoun EA, Santanna J, Landis JR, Kusek JW, Litwin MS; Chronic Prostatitis Collaborative Research Network. Quality of life is impaired in men with chronic prostatitis: the Chronic Prostatitis Collaborative Research Network. J Gen Intern Med. 2001 Oct;16(10):656-62.
[29] Litwin MS, McNaughton-Collins M, Fowler FJ Jr, Nickel JC, Calhoun EA, Pontari MA, Alexander RB, Farrar JT, O'Leary MP. The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network. J Urol. 1999 Aug;162(2):369-75. DOI: 10.1097/00005392-199908000-00022
[30] Propert KJ, Alexander RB, Nickel JC, Kusek JW, Litwin MS, Landis JR, Nyberg LM, Schaeffer AJ; Chronic Prostatitis Collaborative Research Network. Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Urology. 2002 Jun;59(6):870-6. DOI: 10.1016/S0090-4295(02)01601-1
[31] Propert KJ, McNaughton-Collins M, Leiby BE, O'Leary MP, Kusek JW, Litwin MS; Chronic Prostatitis Collaborative Research Network. A prospective study of symptoms and quality of life in men with chronic prostatitis/chronic pelvic pain syndrome: the National Institutes of Health Chronic Prostatitis Cohort study. J Urol. 2006 Feb;175(2):619-23; discussion 623. DOI: 10.1016/S0022-5347(05)00233-8
[32] O'Leary MP, Sant GR, Fowler FJ Jr, Whitmore KE, Spolarich-Kroll J. The interstitial cystitis symptom index and problem index. Urology. 1997 May;49(5A Suppl):58-63.
[33] Parsons M, Toozs-Hobson P. The investigation and management of interstitial cystitis. J Br Menopause Soc. 2005 Dec;11(4):132-9. DOI: 10.1258/136218005775544255
[34] Parsons CL. Diagnosing chronic pelvic pain of bladder origin. J Reprod Med. 2004 Mar;49(3 Suppl):235-42.
[35] Parsons CL, Dell J, Stanford EJ, Bullen M, Kahn BS, Waxell T, Koziol JA. Increased prevalence of interstitial cystitis: previously unrecognized urologic and gynecologic cases identified using a new symptom questionnaire and intravesical potassium sensitivity. Urology. 2002 Oct;60(4):573-8. DOI: 10.1016/S0090-4295(02)01829-0
[36] Quaghebeur J, Wyndaele JJ. Comparison of questionnaires used for the evaluation of patients with chronic pelvic pain. Neurourol Urodyn. 2013 Nov;32(8):1074-9. DOI: 10.1002/nau.22364
[37] Cory L, Harvie HS, Northington G, Malykhina A, Whitmore K, Arya L. Association of neuropathic pain with bladder, bowel and catastrophizing symptoms in women with bladder pain syndrome. J Urol. 2012 Feb;187(2):503-7. DOI: 10.1016/j.juro.2011.10.036
[38] Arya LA, Harvie HS, Andy UU, Cory L, Propert KJ, Whitmore K. Construct validity of an instrument to measure neuropathic pain in women with bladder pain syndrome. Neurourol Urodyn. 2013 Jun;32(5):424-7. DOI: 10.1002/nau.22314
[39] Mathieson S, Lin C. painDETECT questionnaire. J Physiother. 2013 Sep;59(3):211. DOI: 10.1016/S1836-9553(13)70189-9
[40] George AK, Sadek MA, Saluja SS, Fariello JY, Whitmore KE, Moldwin RM. The impact of neuropathic pain in the chronic pelvic pain population. J Urol. 2012 Nov;188(5):1783-7. DOI: 10.1016/j.juro.2012.07.034
[41] Mathieson S, Maher CG, Terwee CB, Folly de Campos T, Lin CW. Neuropathic pain screening questionnaires have limited measurement properties. A systematic review. J Clin Epidemiol. 2015 Aug;68(8):957-66. DOI: 10.1016/j.jclinepi.2015.03.010
[42] Keller ML, McCarthy DO, Neider RS. Measurement of symptoms of interstitial cystitis. A pilot study. Urol Clin North Am. 1994 Feb;21(1):67-71.
[43] Goin JE, Olaleye D, Peters KM, Steinert B, Habicht K, Wynant G. Psychometric analysis of the University of Wisconsin Interstitial Cystitis Scale: implications for use in randomized clinical trials. J Urol. 1998 Mar;159(3):1085-90.
[44] Porru D, Tinelli C, Gerardini M, Giliberto GL, Stancati S, Rovereto B. Evaluation of urinary and general symptoms and correlation with other clinical parameters in interstitial cystitis patients. Neurourol Urodyn. 2005;24(1):69-73. DOI: 10.1002/nau.20084
[45] Clemens JQ, Calhoun EA, Litwin MS, McNaughton-Collins M, Kusek JW, Crowley EM, Landis JR; Urologic Pelvic Pain Collaborative Research Network. Validation of a modified National Institutes of Health chronic prostatitis symptom index to assess genitourinary pain in both men and women. Urology. 2009 Nov;74(5):983-7, quiz 987.e1-3. DOI: 10.1016/j.urology.2009.06.078
[46] Sullivan MJL, Bishop SR, Pivik J. The pain catastrophizing scale: development and validation. Psychol Assess. 1995;7(4):524-32. DOI: 10.1037/1040-3590.7.4.524
[47] Quartana PJ, Campbell CM, Edwards RR. Pain catastrophizing: a critical review. Expert Rev Neurother. 2009 May;9(5):745-58. DOI: 10.1586/ern.09.34
[48] Crawford JR, Henry JD. The positive and negative affect schedule (PANAS): construct validity, measurement properties and normative data in a large non-clinical sample. Br J Clin Psychol. 2004 Sep;43(Pt 3):245-65. DOI: 10.1348/0144665031752934
[49] Jensen MP, Turner JA, Romano JM, Strom SE. The Chronic Pain Coping Inventory: development and preliminary validation. Pain. 1995 Feb;60(2):203-16. DOI: 10.1016/0304-3959(94)00118-X
[50] Nordling J, Anjum FH, Bade JJ, Bouchelouche K, Bouchelouche P, Cervigni M, Elneil S, Fall M, Hald T, Hanus T, Hedlund H, Hohlbrugger G, Horn T, Larsen S, Leppilahti M, Mortensen S, Nagendra M, Oliveira PD, Osborne J, Riedl C, Sairanen J, Tinzl M, Wyndaele JJ. Primary evaluation of patients suspected of having interstitial cystitis (IC). Eur Urol. 2004 May;45(5):662-9. DOI: 10.1016/j.eururo.2003.11.021
[51] Stöhrer M, Blok B, Castro-Diaz D, Chartier-Kastler E, Del Popolo G, Kramer G, Pannek J, Radziszewski P, Wyndaele JJ. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol. 2009 Jul;56(1):81-8. DOI: 10.1016/j.eururo.2009.04.028
[52] Nee RJ, Jull GA, Vicenzino B, Coppieters MW. The validity of upper-limb neurodynamic tests for detecting peripheral neuropathic pain. J Orthop Sports Phys Ther. 2012 May;42(5):413-24. DOI: 10.2519/jospt.2012.3988
[53] Topp KS, Boyd BS. Peripheral nerve: from the microscopic functional unit of the axon to the biomechanically loaded macroscopic structure. J Hand Ther. 2012 Apr-Jun;25(2):142-51; quiz 152. DOI: 10.1016/j.jht.2011.09.002
[54] Topp KS, Boyd BS. Structure and biomechanics of peripheral nerves: nerve responses to physical stresses and implications for physical therapist practice. Phys Ther. 2006 Jan;86(1):92-109.
[55] Mizisin AP, Weerasuriya A. Homeostatic regulation of the endoneurial microenvironment during development, aging and in response to trauma, disease and toxic insult. Acta Neuropathol. 2011 Mar;121(3):291-312. DOI: 10.1007/s00401-010-0783-x
[56] Campbell JN, Meyer RA. Mechanisms of neuropathic pain. Neuron. 2006 Oct;52(1):77-92. DOI: 10.1016/j.neuron.2006.09.021
[57] Butler DS. The sensitive nervous system. Adelaide, Australia: NoiGroup Publications; 2000.
[58] Butler DS. Mobilisation of the nervous system. 7th ed. Melbourne: Churchill Livingstone; 1996.
[59] Shacklock M. Clinical Neurodynamics. A new system of musculoskeletal treatment. Edinburgh: Elsevier; 2005.
[60] Greening J, Lynn B. Minor peripheral nerve injuries: an underestimated source of pain? Man Ther. 1998.3(4):187-94. DOI: 10.1016/S1356-689X(98)80047-7
[61] Nee RJ, Butler D. Management of peripheral neuropathic pain: Integrating neurobiology, neurodynamics, and clinical evidence. Physical Therapy in Sport. 2006. 7(1):36-49. DOI: 10.1016/j.ptsp.2005.10.002
[62] Schmid AB, Brunner F, Luomajoki H, Held U, Bachmann LM, Künzer S, Coppieters MW. Reliability of clinical tests to evaluate nerve function and mechanosensitivity of the upper limb peripheral nervous system. BMC Musculoskelet Disord. 2009 Jan 21;10:11. DOI: 10.1186/1471-2474-10-11
[63] Devor M. Neuropathic pain and injured nerve: peripheral mechanisms. Br Med Bull. 1991 Jul;47(3):619-30.
[64] Curtis Nickel J, Baranowski AP, Pontari M, Berger RE, Tripp DA. Management of men diagnosed with chronic prostatitis/chronic pelvic pain syndrome who have failed traditional management. Rev Urol. 2007;9(2):63-72.
[65] Itza Santos F, Salinas J, Zarza D, Gómez Sancha F, Allona Almagro A. Update in pudendal nerve entrapment syndrome: an approach anatomic-surgical, diagnostic and therapeutic. Actas Urol Esp. 2010 Jun;34(6):500-9. DOI: 10.4321/S0210-48062010000600003
[66] Quaghebeur J. Research on diagnostic techniques used in CPPS patients. PhD thesis. Wilrijk, Belgium: Antwerp University; 2014.
[67] Quaghebeur J, Wyndaele JJ, De Wachter S. Pain areas and mechanosensitivity in patients with chronic pelvic pain syndrome: a controlled clinical investigation. Scand J Urol. 2017 Jul 5:1-6. DOI: 10.1080/21681805.2017.1339291
[68] Katims JJ. Electrodiagnostic functional sensory evaluation of the patient with pain: A review of the neuroselective current perception threshold and pain tolerance threshold. Pain Dig. 1998;8:219-30.
[69] Quaghebeur J, Wyndaele JJ. Variability of pudendal and median nerve sensory perception thresholds in healthy persons. Neurourol Urodyn. 2015 Apr;34(4):327-31. DOI: 10.1002/nau.22565
[70] Quaghebeur J, Wyndaele JJ. Pudendal and median nerve sensory perception threshold: a comparison between normative studies. Somatosens Mot Res. 2014 Dec;31(4):186-90. DOI: 10.3109/08990220.2014.911172
[71] Mittal T, Kumar V, Khullar R, Sharma A, Soni V, Baijal M, Chowbey PK. Diagnosis and management of Spigelian hernia: A review of literature and our experience. J Minim Access Surg. 2008 Oct;4(4):95-8. DOI: 10.4103/0972-9941.45204
[72] Nazareno J, Ponich T, Gregor J. Long-term follow-up of trigger point injections for abdominal wall pain. Can J Gastroenterol. 2005 Sep;19(9):561-5. DOI: 10.1155/2005/274181
[73] Isherwood PJ, Rane A. Comparative assessment of pelvic floor strength using a perineometer and digital examination. BJOG. 2000 Aug;107(8):1007-11.
[74] Frawley HC, Galea MP, Phillips BA, Sherburn M, Bø K. Reliability of pelvic floor muscle strength assessment using different test positions and tools. Neurourol Urodyn. 2006;25(3):236-42. DOI: 10.1002/nau.20201
[75] Maigne JY, Doursounian L, Chatellier G. Causes and mechanisms of common coccydynia: role of body mass index and coccygeal trauma. Spine. 2000 Dec;25(23):3072-9. DOI: 10.1097/00007632-200012010-00015
[76] Simons DG, Travell JG, Simons LS. Travell & Simons' Myofascial pain and dysfunction the trigger point manual: Volume 1: the upper half of body. 2nd ed. Baltimore, MD: Williams & Wilkins; 1999.
[77] McPartland JM, Simons DG. Myofascial trigger points translating molecular theory into manual therapy. J Man Manip Ther. 2006. 14(4):232-9. DOI: 10.1179/106698106790819982
[78] Anderson RU, Wise D, Sawyer T, Chan C. Integration of myofascial trigger point release and paradoxical relaxation training treatment of chronic pelvic pain in men. J Urol. 2005 Jul;174(1):155-60. DOI: 10.1097/01.ju.0000161609.31185.d5
[79] Wise D, Anderson R. A Headache in the Pelvis. A new understanding and treatment for prostatitis and chronic pelvic pain syndromes. 4th ed. Occidental, CA: National Center for Pelvic Pain Research; 2006.
[80] Carter JE. Chronic Pelvic Pain Diagnosis and Management. New York: Lippincott Williams & Wilkins; 2001.
[81] Epstein O, Perkin D, Cookson J, De Bono D. Clinical Examination. 3rd ed. Edinburgh: Mosby; 2003.
[82] Tu FF, Holt J, Gonzales J, Fitzgerald CM. Physical therapy evaluation of patients with chronic pelvic pain: a controlled study. Am J Obstet Gynecol. 2008 Mar;198(3):272.e1-7. DOI: 10.1016/j.ajog.2007.09.002

The ZB MED – Information Center for Life Sciences, Germany, together with the European Association of Urology (EAU) provided the opportunity to publish a “Living Textbook” on “Urogenital Infections and Inflammations” in an open access form. This “Living Textbook” represents also an update of the Textbook on Urogenital Infections published 2010 by the International Consultation on Urological Infections and the EAU: http://www.icud.info/urogenitalinfections.html.

The “Living Textbook” will cover infections and inflammations of the kidney, the urinary tract, as well as the male and female genital tract considering pathogenesis, diagnostics, treatment, prophylaxis and future aspects. The “Living Textbook” will be structured into about 26 Sections each with two section co-chairs responsible for peer review of the chapters of each section. Each chapter should reflect the background to the topic and highlight all of the critical evidence relating to the subject. The intention is to provide an up to date, concise synthesis of the literature on that topic, and for clinical topics also recommendations based on levels of evidence for contemporary clinical practice, as well as suggested research recommendations.

The editors hope that this “Living Textbook” may become a useful instrument for physicians of different specialties taking care about patients suffering from these diseases.

Truls E. Bjerklund Johansen (Norway),

Florian ME Wagenlehner (Germany),

Yong-Hyun Cho (South Korea),

Tetsuro Matsumoto (Japan),

John N Krieger (USA),

Daniel Shoskes (USA),

Kurt G. Naber (Germany).

Publishing at PUBLISSO

Your chapter will be published at the PUBLISSO platform (https://books.publisso.de).

Information for corresponding authors

It is necessary for all corresponding authors to register at PUBLISSO.
To register at PUBLISSO please click the following link: http://books.publisso.de/publisso_gold/register

After registration, please complete your user profile. Information from your user profile will appear in the published chapter and the authors board of the book (http://books.publisso.de/publisso_gold/book/52). If you are displayed in the authors board, you can be contacted by readers and other professionals. You can also contact other authors of the book for exchange and to build a network.
(If you do not want to be displayed in the authors board, but stay registered, you can disable this feature in your profile settings. In this case, your affiliation (publication data) will be displayed in the published chapter only.)

We kindly ask you to provide the co-authors email addresses in the manuscript so that we can contact them in case of queries.

Information for co-authors

After publication of your chapter, your affiliation (publication data) will be displayed in the published chapter.

If you also want to be displayed in the authors board of the book (http://books.publisso.de/publisso_gold/book/52), we kindly ask you to register at PUBLISSO. If you are displayed in the authors board, you can be contacted by readers and other professionals. You can also contact other authors of the book for exchange and to build a network.

To register at PUBLISSO please click the following link: http://books.publisso.de/publisso_gold/register

If you do not want to be displayed in the authors board of the book, you do not have to register. Your affiliation (publication data) will be displayed in the published chapter only.

Support

If you have any further questions please don’t hesitate to contact the PUBLISSO editorial office:

E-Mail: livingbooks@zbmed.de
Phone: +49 221 478-7093

General

The textbook will be structured in sections with two co-chairs each. Each section will start with an introductory chapter written by the two respective co-chairs presented like an editorial commentary in regard to the following chapters (see proposed contents of the book). The two co-chairs of each section will also peer review all chapters in their section and stimulate a consensus discussion within their section together with the authors and the main editors if needed.

Chapters

Each chapter should reflect the background to the topic and highlight all of the critical evidence relating to the subject. The intention is to provide an up to date, concise synthesis of the literature on that topic, and for clinical topics also recommendations based on levels of evidence for contemporary clinical practice, as well as suggested research recommendations.

Manuscript

Each manuscript should have up to approximately 3,000 words (excluding abstract, tables/figures and references). The abstract should count about 300 words.

Structure

The outline of each chapter should be structured as follows (similar as in the edition 2010, which can be downloaded for free: http://www.icud.info/urogenitalinfections.html):

  1. Abstract
  2. Summary of recommendations*/key notes*
    (*which ever term is more appropriate)
  3. Introduction
  4. Methods
  5. Results
  6. Further research
  7. Conclusions
  8. Acknowledgement
  9. Conflict of interest of each author
  10. References

Citation style

As a citation style, the Vancouver style is preferred.

Please mark your references in the text with square brackets ([1], [2], ...).

Summary of recommendations

We would like to have the Summary of recommendations at the beginning after the abstract (as in the edition 2010). However, we do not expect as in the edition 2010, that each recommendation is also specified according to Level of Evidence and Grade of Recommendation, because such a claim would not only need a systematic literature search (see below), but also a structured discussion in a defined group of experts.

Systematic literature search

A systematic literature search should be performed, at least of PUBMED/MEDLINE but ideally of several relevant databases in addition (like Cochrane CENTRAL) to find recent, high quality systematic reviews and/or primary research studies. It is not expected to perform for all chapters a de novo systematic review, if such reviews are already published recently, but it still may be indicated for some items. For questions relating therapy, it should be focused on evidence from (systematic reviews of) randomized controlled trials if available.

The method of the systematic literature search needs to be fully described in the section “Methods”, e.g.:

“A systematic literature search was performed for the last ... (usually 10) years in MEDLINE, Cochrane etc. with the following key words ... and the following limitations: e.g. UTI, age (adult?), ... clinical studies ... English ... abstract available ... only peer reviewed ...

A total of ... publications were identified, which were screened by title and abstract ... After exclusion of duplicates ... a total of ... were included into the review (analysis), supplemented by citations or known to the authors ... ”.

Clinical topics

Clinical topics should be focused on the importance to clinical practice according to the up to date scientific knowledge as presented in the literature. It should relate to questions/complaints/symptoms of patient/population concerning definition, diagnosis, therapy/prevention, intervention, and outcome in comparison, if different approaches are feasible. Please choose patient-important outcomes and focus on those, which you deem critical for decision-making.

Level of evidence and grade of recommendations

Any recommendation should be based on the level of evidence and the grade of recommendation. For this purpose the following system, modified from the Oxford Centre for Evidence-based Medicine should be used (EAU guidelines 2015):

Level of evidence (LE)

Level Type of evidence
1a Evidence obtained from meta-analysis of randomised trials
1b Evidence obtained from at least one randomised trial
2a Evidence obtained from one well-designed controlled study without randomization
2b Evidence obtained from at least one other type of well-designed quasi-experimental study
3 Evidence obtained from well-designed non-experimental studies, such as comparative studies, correlation studies and case reports.
4 Evidence obtained from expert committee reports or opinions or clinical experience of respected authorities.

Grade of Recommendations (GoR)

Grade Nature of recommendations
A Based on clinical studies of good quality and consistency addressing the specific recommendations and including at least one randomised trial
B Based on well-conducted clinical studies, but without randomised clinical trials
C Made despite the absence of directly applicable clinical studies of good quality

Comments (EAU guidelines 2015)

The aim of assigning a LE and grading recommendations is to provide transparency between the underlying evidence and the recommendation given.

It should be noted that when recommendations are graded, the link between the level of evidence and grade of recommendation is not directly linear. Availability of randomized controlled trials may not necessarily translate into a grade “A” recommendation where there are methodological limitations or disparity in published results.

Alternatively, absence of high level evidence does not necessarily preclude a grade A recommendation, if there is overwhelming clinical experience and consensus. In addition, there may be exceptional situations where corroborating studies cannot be performed, perhaps for ethical or other reasons and in this case unequivocal recommendations are considered helpful for the reader. The quality of the underlying scientific evidence - although a very important factor – has to be balanced against benefits and burdens, values and preferences and costs when a grade is assigned.

Since the same rating system should be used in all chapters, for the sake of brevity the same sentence could be used in “Methods” for all manuscripts, because the rating system will be described in details in the Preface of the book:

“The studies were rated according to the level of evidence and the strength of recommendations graded according to a system used in the EAU guidelines modified from the Oxford Centre for Evidence-based Medicine [1].”

References

[1] European Association of Urology. Guidelines. Methodology section. 2015 ed. Arnhem: European Association of Urology; 2015. p. 3. ISBN/EAN: 978-90-79754-80-9. Available from: http://uroweb.org/wp-content/uploads/EAU-Extended-Guidelines-2015-Edn..pdf

The Living Handbook of Urogenital Infections and Inflammations is issued by:

European Association of Urology
att. Maurice Schlief, EAU executive manager business affairs

P.O.Box 30016
NL-6803 AA Arnhem, The Netherlands

Phone: 0031-26-38.90.680
E-mail: m.schlief@uroweb.org

Editor in Chief

responsible for the contents according to § 5 TMG and § 55 Abs. 2 RStV (Germany):

Kurt G. Naber, MD, PhD
Assoc. Professor of Urology

Technical University of Munich
Karl-Bickleder-Str. 44c
94315 Straubing, Germany

E-mail: kurt.naber@nabers.de

John N. Krieger MD, PhD

University of Washington Section of Urology

more

Daniel Shoskes MD, PhD

Cleveland Clinic Glickman Urological and Kidney Institute

more

Yong-Hyun Cho MD, PhD

St. Mary's Hospital, The Catholic University of Korea Department of Urology

more

Tetsuro Matsumoto MD, PhD

University of Occupational and Environmental Health Department of Urology

more

Florian M. E. Wagenlehner MD, PhD

Justus-Liebig University of Giessen Clinic of Urology and Andrology

more

Truls Erik Bjerklund Johansen MD, PhD

Oslo University Hospital Urology Department

more

Kurt G. Naber MD, PhD

Technical University of Munich

more

Riccardo Bartoletti

University of Pisa
Department of Translational Research and New Technologies

more

Truls Erik Bjerklund Johansen MD, PhD

Oslo University Hospital
Urology Department

more

PD Dr. med. Gernot Bonkat

University Basel
alta uro AG, Merian Iselin Klinik, Center of Biomechanics & Calorimetry (COB)

more

Prof. Tommaso Cai MD

Santa Chiara Regional Hospital
Dept. of Urology

more

Dr Leyland Chuang

Ng Teng Fong Hospital, National University Health System
Department of Medicine

more

Prof. Milan Cizman

University Medical Centre
Department of Infectious Diseases

more

Alison Crawford MSc

Queen's University
Department of Psychology

more

Pfofessor Svetlana Dubrovina MD, PhD

Rostov Medical State University
Obstetrics and Gynaecology

more

Dr Valerie Huei Li Gan MBBS (S'pore), MRCS (Edin), MMed (Surg), FAMS (Urology)

Singapore General Hospital
Department of Urology

more

Philip Hanno

University of Pennsylvania

more

Ass prof MD Gundela Holmdahl

Queen Silvia Childrens Hospital, Sahlgrens Academy
Pediatric surgery and urology

more

Udo B. Hoyme

HELIOS Hospital Erfurt Ltd.
Department of Gynecology and Obstetrics

more

David Hunstad

Washington University School of Medicine
Pediatrics / Molecular Microbiology

more

Gitte M. Hvistendahl

Aarhus University Hospital

more

Prof. Michael KOGAN M.D., PhD

Rostov State Medical University
Department of Urology

more

Dr Akihiro Kanematsu

Hyogo College of Medicine
Department of Urology

more

Frieder Keller

University Hospital Ulm
Department Internal Medicine 1, Nephrology

more

Professor Katarzyna Kilis-Pstrusinska PhD, MD

Wroclaw Medical University
Department of Pediatric Nephrology

more

MD, PhD Tae-Hyoung Kim

Chung-Ang University
Urology

more

John N. Krieger MD, PhD

University of Washington
Section of Urology

more

Prof Ekaterina Kulchavenya

Novosibirsk Research TB Institute, Novosibirsk State Medical University

more

Dr Christina Kåbjörn Gustafsson

Ryhov Hospital Jönköping
Pathology

more

Dr. Bela Köves

South Pest Teaching Hospital
Department of Urology

more

Dr. med. Giuseppe Magistro

Ludwig-Maximilians-University of Munich
Department of Urology

more

Vittorio Magri

ASST-North
Urologic Clinic

more

András Magyar

South-Pest Hospital
Department of Urology

more

Professor Emeritus Brian Morris

University of Sydney
School of Medical Sciences

more

Baerbel Muendner-Hensen

ICA-Deutschland e.V.

more

Stephen F. Murphy

Feinberg School of Medicine, Northwestern University
Department of Urology

more

Kurt G. Naber MD, PhD

Technical University of Munich

more

Prof. Yulia Naboka

Rostov State Medical University
Department of Microbiology

more

Dr. J. Curtis Nickel MD

Queen's University
Department of Urology

more

Professor Ralph Peeker MD PhD

University of Gothenburg
Department of Urology

more

Tamara Perepanova

N.A. Lopatkin Research Institute of Urology and Interventional Radiology

more

Prof. Gianpaolo Perletti M. Clin. Pharmacol.

University of Insubria
Department of Biotechnology and Life Sciences

more

Felice Petraglia

Department of Biomedical, Experimental and Clinical Sciences, University of Florence
Obstetrics and Gynecology

more

Dr. Jörgen Quaghebeur PhD. Med. Sci.

University Hospital Antwerp and University Antwerp
Department of Urology

more

Yazan F. Rawashdeh

Aarhus University Hospital
Paediatric Urology Section, Department of Urology

more

Professor Claus Riedl MD

-
Urology

more

Matthew Roberts

The University of Queensland
Faculty of Medicine

more

PD Dr. med Guido Schmiemann MPH

Institut für Public Health und Pflegeforschung, Universität Bremen
Abteilung Versorgungsforschung

more

Caroline Schneeberger MD PhD

Academic Medical Center (AMC)

more

Prof. Dr. med. Peter Schneede

Klinikum Memmingen
Department of Urology

more

Aaron C. Shoskes

Des Moines University Medical College of Ostheopathic Medicine

more

Daniel Shoskes MD, PhD

Cleveland Clinic
Glickman Urological and Kidney Institute

more

Prof. Dr. Roswitha Siener

University of Bonn
University Stone Centre, Department of Urology

more

Sofia Sjöström

Queen Silvia Childrens Hospital, Sahlgrens Academy
Pediatric surgery and urology

more

Mathew Sorensen

University of Washington School of Medicine
Department of Urology

more

Prof. Dr. Dr. Walter Ludwig Strohmaier FEBU

Regiomed-Klinikum Coburg. Medical School Regiomed
Urology and Paediatric Urology

more

Satoshi Takahashi

Sapporo Medical University School of Medicine
Department of Infection Control and Laboratory Medicine

more

Professor Paul Anantharajah Tambyah

Yong Loo Lin School of Medicine, National University Hospital
Department of Medicine

more

Peter Tenke

South-Pest Hospital
Department of Urology

more

Praveen Thumbikat


Department of Urology

more

Dr. Jose Tiran Saucedo

IMIGO / Universidad de Monterrey
Obstetrics and Gynaecology

more

Dominic Tran-Nguyen

Des Moines University

more

Dean Tripp

Queen's University
Psychology, Anesthesia & Urology

more

Prof. SEONGHEON WIE

The Catholic University of Korea, St. Vincent's Hospital
Division of Infectious Diseases, Department of Internal Medicine

more

Florian M. E. Wagenlehner MD, PhD

Justus-Liebig University of Giessen
Clinic of Urology and Andrology

more

Assoc. Prof. Christian Wejse

Aarhus University, Aarhus University Hospital
Department of Infectious Diseases/Center for Global Health, Dept of Public Health

more

Prof. Dr. Mete Çek

Trakya University, School of Medicine
Urology

more